Previously, we have described the nanobody-PS or VHH-PS conjugates specifically targeting the epidermal growth factor receptor (EGFR), a receptor tyrosine kinase (RTK) that is found overexpressed on a large variety of cancers, such as head and neck, lung, or colon cancer [17,18]. Here, EGFR is linked to malignant colon neoplasm.